期刊文献+

胃粘膜内肥大细胞及其脱颗粒在HP致病中的作用 被引量:2

A STUDY ON THE ROLES OF MAST CELLS AND THEIR DEGRANULATION IN GASTRIC MUCOSA IN THE PATHOPOIESIS OF H. PYLORI
下载PDF
导出
摘要 目的 :探讨胃粘膜肥大细胞及其脱颗粒在HP感染中的致病作用。方法 :采用改良甲苯胺兰染色法检测了 14 2例患者胃粘膜中肥大细胞及其脱颗粒情况。结果 :HP阳性者胃粘膜内肥大细胞总数 ( 8.11)及脱颗粒比值 ( 4 7.65 % )均显著高于HP阴性者 ( 4 .2 2 ,3 1.3 2 % ) (P <0 .0 1) ;慢性活动性胃炎及中重度胃炎胃粘膜内肥大细胞总数 ( 8.73 ,8.79)及脱颗粒比值 ( 5 7.4 2 % ,5 7.74 % )均显著高于非活动性胃炎 ( 5 .5 4 ,3 5 .0 1% )和轻度胃炎 ( 5 .68,3 5 .5 6% ) (P <0 .0 1~ 0 .0 0 1)。结论 :肥大细胞及其脱颗粒参与了HP的致病过程而导致胃粘膜损伤。 Objective: To study the roles of mast cells and their degranulation in gastric mucosa in the pathopoiesis of H. Pylori. Methods Adopting improved Toluidine Blue Staining, we examined the gastric mucosal mast cells (MC) and their degranulation in 159 patients. Results The total amount of gastric mucosal MC (8.11) and the degranulation portion (47.65%) in the patients with positive H. Pylori were significantly higher than that in the patients with negative H. Pylori (4.22 and 31.32%) respectively ( P <0.01). The above two parameters in chronic active gastritis (8.73, 57.42%) and in moderate-severe gastritis (8.79,57.74%) were significantly higher than those in inactive gastritis (5.54,35.01%) and in mild gastritis (5.68, 35.56%) respectively ( P <0.01 or P <0.001). Conclusions MC and its degranulation in gastric mucosa may participate in the pathopoiesis of H. Pylori and cause gastric mucosal injury.
出处 《中国内镜杂志》 CSCD 2000年第1期9-10,共2页 China Journal of Endoscopy
关键词 幽门螺杆菌 肥大细胞 胃粘膜 致病机理 Helicobacter Pylori Mast Cells Gastritis
  • 相关文献

参考文献2

二级参考文献38

  • 1田英,龙石银,徐燕华,傅明德,张雪梅,刘秉文.Ⅳ型高脂血症患者高密度脂蛋白亚类组成与载脂蛋白E基因多态性关系的研究[J].中华医学遗传学杂志,2005,22(1):96-98. 被引量:16
  • 2American College of Obstetricians and Gynecologists; Task Force Hypertension in Pregnancy. Hypertension in pregnancy. (on) Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy [ J]. Obstet Gynecol, 2013, 122(5) :1122-1131.
  • 3Magee LA, Pels A, Helewa M, et al. Canadian Hypertensive Disorders of Pregnancy Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary [ J]. J Obstet Gynaecol Can, 2014, 36 (5) : 416-441.
  • 4Visintin C, Mugglestone MA, Almerie MQ, et al. Management of hypertensive disorders during pregnancy: summary of NICE guidance[J]. BMJ, 2010, 341 :c2207.
  • 5Lowe SA, Bowyer L, Lust K, et al. The SOMANZ Guidelines for the Management of Hypertensive Disorders of Pregnancy 2014 [ J ]. Aust N Z J Obstet Gynaecol, 2015, 55 (1) :11-16.
  • 6Campos-Outcalt D Sr. US Preventive Services Task Force: the gold standard of evidence-based prevention [ J ]. J Fam Pract, 2005, 54(6) :517-519.
  • 7Magee LA, Hdewa M, Momquin JM, et al. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy[ J]. J Obstet Gynaeeol Can, 2008, 30 (Suppl) : S1- 48.
  • 8Cote AM, Brown MA, Lain E, ct ai. Diagnostic accuracy of urinary spot protein : creatinine ratio for proteinuria in hypertensive pregnant women: systematic review [ J ]. BMJ, 2008, 336 (7651) :1003-1006.
  • 9Churchill D, Beevers GD, Meher S, et al. Diuretics for preventing pre-eclampsia[ J]. Cochrane Database Syst Rev,2007, 24( 1 ) : CD004451.
  • 10McCoy S, Baldwin K. Pharmaeotherapeutie options for the treatment of preeelampsia[ J]. Am J Health Syst Pharm, 2009,66 (4) :337-344.

共引文献247

同被引文献23

引证文献2

二级引证文献47

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部